A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia

Trial Profile

A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Pomalidomide (Primary)
  • Indications Anaemia; Haemorrhage
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jan 2018 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
    • 23 Jan 2018 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2018.
    • 06 Dec 2016 Status changed from not yet recruiting to recruiting, according to interim results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top